Purpose: Current guidelines recommend vaccination at least 2 weeks before chemotherapy initiation to optimize the immune response despite limited evidence. Our previous study indicated no differences in short-term immune response for the 13-valent pneumococcal conjugate vaccine (PCV13) according to the vaccination timing. This study aims to investigate the long-term efficacy of PCV13 and clinical factors associated with the respective antibody response. Materials and Methods: Patients with gastric or colorectal cancer who received adjuvant chemotherapy were enrolled and divided into two groups: vaccinated 2 weeks before chemotherapy (arm A) and vaccinated concurrently with chemotherapy (arm B). Serum samples were collected before vaccination and in one month, 3 years, and 5 years. Immune responses were measured using enzyme-linked immunosorbent assay and multiplex opsonophagocytosis assay. Results: Including 63 patients, both groups showed an initial increase in the geometric mean titers of opsonophagocytic activity and the geometric mean concentrations of serotype-specific IgG levels after one month, followed by a decline at 3 and 5 years, particularly for serotypes 1, 14, 18C, and 19A. Despite the decline, global protection was maintained for 5 years, although global response decreased. The two arms did not show significant differences in immunogenicity nor in factors such as vaccination timing, age, cancer type, or chemotherapy regimen. Conclusion Vaccination timing is not a significant factor for the immunogenicity of PCV13 in cancer patients undergoing adjuvant chemotherapy. Global protection against pneumococcal infection was sustained for > 5 years, and global response remained in over half of patients.

Objective: In this study, we aimed to investigate how fetal head and abdominal circumferences are related to the incidence of neonatal complications in mothers with gestational diabetes mellitus (GDM) and pre-gestational diabetes mellitus (PGDM) compared to normal pregnancies. Methods: We retrospectively analyzed data of expectant mothers with GDM, PGDM, and normal pregnancies who delivered singleton full-term infants (≥37 weeks) at a tertiary center from January 2013 to December 2022. Ultrasonography-measured fetal weight, fetal head circumference, fetal abdominal circumference, difference between head and abdominal circumference, and head-to-abdominal circumference ratio were assessed. Neonatal outcomes were evaluated based on the rates of admission to the neonatal intensive care unit, intubation, and hypoglycemia. Statistical analyses, including univariate and multivariate analyses, were performed using the SPSS software (IBM Corp., Armonk, NY, USA). Results: Among the 473 participants, 175 (37.0%) were mothers with diabetes (DM). A head-to-abdominal circumference ratio <0.95 and a difference of ≥2.5 cm were significantly associated with neonatal hypoglycemia in all mothers with DM, with statistical significance noted only in the PGDM group. No significant association was observed in normal pregnancies. Conclusion Our findings indicate that a head-to-abdominal circumference ratio <0.95 and a ≥2.5 cm difference in circumferences are associated with neonatal hypoglycemia in mothers with DM.

Objective: In this study, we aimed to investigate how fetal head and abdominal circumferences are related to the incidence of neonatal complications in mothers with gestational diabetes mellitus (GDM) and pre-gestational diabetes mellitus (PGDM) compared to normal pregnancies. Methods: We retrospectively analyzed data of expectant mothers with GDM, PGDM, and normal pregnancies who delivered singleton full-term infants (≥37 weeks) at a tertiary center from January 2013 to December 2022. Ultrasonography-measured fetal weight, fetal head circumference, fetal abdominal circumference, difference between head and abdominal circumference, and head-to-abdominal circumference ratio were assessed. Neonatal outcomes were evaluated based on the rates of admission to the neonatal intensive care unit, intubation, and hypoglycemia. Statistical analyses, including univariate and multivariate analyses, were performed using the SPSS software (IBM Corp., Armonk, NY, USA). Results: Among the 473 participants, 175 (37.0%) were mothers with diabetes (DM). A head-to-abdominal circumference ratio <0.95 and a difference of ≥2.5 cm were significantly associated with neonatal hypoglycemia in all mothers with DM, with statistical significance noted only in the PGDM group. No significant association was observed in normal pregnancies. Conclusion Our findings indicate that a head-to-abdominal circumference ratio <0.95 and a ≥2.5 cm difference in circumferences are associated with neonatal hypoglycemia in mothers with DM.

Objective: In this study, we aimed to investigate how fetal head and abdominal circumferences are related to the incidence of neonatal complications in mothers with gestational diabetes mellitus (GDM) and pre-gestational diabetes mellitus (PGDM) compared to normal pregnancies. Methods: We retrospectively analyzed data of expectant mothers with GDM, PGDM, and normal pregnancies who delivered singleton full-term infants (≥37 weeks) at a tertiary center from January 2013 to December 2022. Ultrasonography-measured fetal weight, fetal head circumference, fetal abdominal circumference, difference between head and abdominal circumference, and head-to-abdominal circumference ratio were assessed. Neonatal outcomes were evaluated based on the rates of admission to the neonatal intensive care unit, intubation, and hypoglycemia. Statistical analyses, including univariate and multivariate analyses, were performed using the SPSS software (IBM Corp., Armonk, NY, USA). Results: Among the 473 participants, 175 (37.0%) were mothers with diabetes (DM). A head-to-abdominal circumference ratio <0.95 and a difference of ≥2.5 cm were significantly associated with neonatal hypoglycemia in all mothers with DM, with statistical significance noted only in the PGDM group. No significant association was observed in normal pregnancies. Conclusion Our findings indicate that a head-to-abdominal circumference ratio <0.95 and a ≥2.5 cm difference in circumferences are associated with neonatal hypoglycemia in mothers with DM.

Objective: In this study, we aimed to investigate how fetal head and abdominal circumferences are related to the incidence of neonatal complications in mothers with gestational diabetes mellitus (GDM) and pre-gestational diabetes mellitus (PGDM) compared to normal pregnancies. Methods: We retrospectively analyzed data of expectant mothers with GDM, PGDM, and normal pregnancies who delivered singleton full-term infants (≥37 weeks) at a tertiary center from January 2013 to December 2022. Ultrasonography-measured fetal weight, fetal head circumference, fetal abdominal circumference, difference between head and abdominal circumference, and head-to-abdominal circumference ratio were assessed. Neonatal outcomes were evaluated based on the rates of admission to the neonatal intensive care unit, intubation, and hypoglycemia. Statistical analyses, including univariate and multivariate analyses, were performed using the SPSS software (IBM Corp., Armonk, NY, USA). Results: Among the 473 participants, 175 (37.0%) were mothers with diabetes (DM). A head-to-abdominal circumference ratio <0.95 and a difference of ≥2.5 cm were significantly associated with neonatal hypoglycemia in all mothers with DM, with statistical significance noted only in the PGDM group. No significant association was observed in normal pregnancies. Conclusion Our findings indicate that a head-to-abdominal circumference ratio <0.95 and a ≥2.5 cm difference in circumferences are associated with neonatal hypoglycemia in mothers with DM.

Objective: In this study, we aimed to investigate how fetal head and abdominal circumferences are related to the incidence of neonatal complications in mothers with gestational diabetes mellitus (GDM) and pre-gestational diabetes mellitus (PGDM) compared to normal pregnancies. Methods: We retrospectively analyzed data of expectant mothers with GDM, PGDM, and normal pregnancies who delivered singleton full-term infants (≥37 weeks) at a tertiary center from January 2013 to December 2022. Ultrasonography-measured fetal weight, fetal head circumference, fetal abdominal circumference, difference between head and abdominal circumference, and head-to-abdominal circumference ratio were assessed. Neonatal outcomes were evaluated based on the rates of admission to the neonatal intensive care unit, intubation, and hypoglycemia. Statistical analyses, including univariate and multivariate analyses, were performed using the SPSS software (IBM Corp., Armonk, NY, USA). Results: Among the 473 participants, 175 (37.0%) were mothers with diabetes (DM). A head-to-abdominal circumference ratio <0.95 and a difference of ≥2.5 cm were significantly associated with neonatal hypoglycemia in all mothers with DM, with statistical significance noted only in the PGDM group. No significant association was observed in normal pregnancies. Conclusion Our findings indicate that a head-to-abdominal circumference ratio <0.95 and a ≥2.5 cm difference in circumferences are associated with neonatal hypoglycemia in mothers with DM.

The emergence of the omicron variant and its sub-lineages has necessitated vaccine updates for coronavirus disease 2019. In September 2023, the U.S. Food and Drug Administration approved an updated BNT162b2 vaccine targeting the omicron XBB.1.5 variant, which was initiated in Korea in October 2024. This study demonstrates the adverse events reported through active nationwide surveillance after XBB.1.5 vaccination in Korea. Since October 19, 2023, the Korea Disease Control and Prevention Agency has conducted daily Short Message Service surveys to collect data on health issues, fever, vaccination site reactions, systemic symptoms, impact on daily life, and healthcare visits. Among 20,180 respondents, 27.9% reported health issues. Adverse reactions peaked on day 1 (28.7%), including pain at the vaccination site, muscle pain, fatigue, and fever. These findings elucidate the short-term safety of the XBB.1.5 vaccine and support its co-administration with the influenza vaccine, reducing vaccine hesitancy and achieving herd immunity.

Background: and Purpose Fatigue is common in demyelinating disorders of the central nervous system (CNS), including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).We aimed to validate the usefulness of the Functional Assessment of Chronic Illness Therapy– Fatigue (FACIT-F) and the Fatigue Severity Scale (FSS) relative to the Korean version of the Modified Fatigue Impact Scale (MFIS-K) in Korean patients with MS, NMOSD, and MOGAD. Methods: There were 294 patients with MS (n=120), NMOSD (n=103), or MOGAD (n=71) enrolled in a prospective demyelinating CNS registry. Fatigue was measured using the FACIT-F, MFIS-K, and FSS. Sleep quality, quality of life, depression, and pain were evaluated using the Pittsburgh Sleep Quality Index (PSQI), 36-item Short-Form Survey (SF-36), and Beck Depression Inventory-II (BDI-II). Results: The MFIS-K, FACIT-F, and FSS scores showed high internal consistencies and strong correlations with each other in the MS, NMOSD, and MOGAD groups. The scores on all three fatigue scales were correlated with PSQI, SF-36, and BDI-II results in the three groups. The areas under the receiver operating characteristic curves for the FSS and FACIT-F were 0.834 and 0.835, respectively, for MS, 0.877 and 0.833 for NMOSD, and 0.925 and 0.883 for MOGAD. Conclusions These results suggest that the MFIS-K, FSS, and FACIT-F are useful and valuable assessment instruments for evaluating fatigue in Korean patients with MS, NMOSD, and MOGAD.

Background: During the coronavirus disease 2019 (COVID-19) pandemic, patients with myasthenia gravis (MG) were more susceptible to poor outcomes owing to respiratory muscle weakness and immunotherapy. Several studies conducted in the early stages of the COVID-19 pandemic reported higher mortality in patients with MG compared to the general population. This study aimed to investigate the clinical course and prognosis of COVID-19 in patients with MG and to compare these parameters between vaccinated and unvaccinated patients in South Korea. Methods: This multicenter, retrospective study, which was conducted at 14 tertiary hospitals in South Korea, reviewed the medical records and identified MG patients who contracted COVID-19 between February 2022 and April 2022. The demographic and clinical characteristics associated with MG and vaccination status were collected. The clinical outcomes of COVID-19 infection and MG were investigated and compared between the vaccinated and unvaccinated patients. Results: Ninety-two patients with MG contracted COVID-19 during the study. Nine (9.8%) patients required hospitalization, 4 (4.3%) of whom were admitted to the intensive care unit. Seventy-five of 92 patients were vaccinated before contracting COVID-19 infection, and 17 were not. During the COVID-19 infection, 6 of 17 (35.3%) unvaccinated patients were hospitalized, whereas 3 of 75 (4.0%) vaccinated patients were hospitalized (P < 0.001). The frequencies of ICU admission and mechanical ventilation were significantly lower in the vaccinated patients than in the unvaccinated patients (P = 0.019 and P = 0.032, respectively). The rate of MG deterioration was significantly lower in the vaccinated patients than in the unvaccinated patients (P = 0.041). Logistic regression after weighting revealed that the risk of hospitalization and MG deterioration after COVID-19 infection was significantly lower in the vaccinated patients than in the unvaccinated patients. Conclusion This study suggests that the clinical course and prognosis of patients with MG who contracted COVID-19 during the dominance of the omicron variant of COVID-19 may be milder than those at the early phase of the COVID-19 pandemic when vaccination was unavailable. Vaccination may reduce the morbidity of COVID-19 in patients with MG and effectively prevent MG deterioration induced by COVID-19 infection.

The emergence of the omicron variant and its sub-lineages has necessitated vaccine updates for coronavirus disease 2019. In September 2023, the U.S. Food and Drug Administration approved an updated BNT162b2 vaccine targeting the omicron XBB.1.5 variant, which was initiated in Korea in October 2024. This study demonstrates the adverse events reported through active nationwide surveillance after XBB.1.5 vaccination in Korea. Since October 19, 2023, the Korea Disease Control and Prevention Agency has conducted daily Short Message Service surveys to collect data on health issues, fever, vaccination site reactions, systemic symptoms, impact on daily life, and healthcare visits. Among 20,180 respondents, 27.9% reported health issues. Adverse reactions peaked on day 1 (28.7%), including pain at the vaccination site, muscle pain, fatigue, and fever. These findings elucidate the short-term safety of the XBB.1.5 vaccine and support its co-administration with the influenza vaccine, reducing vaccine hesitancy and achieving herd immunity.